Sanofi India gains after subsidiary in talks bring first dengue vaccine to India

The Sanofi logo is seen at the company's headquarters in Lyon, France. Photo: Reuters
Shares of Sanofi India are up over 2% at Rs 4,331 on the BSE after Sanofi Pasteur, the vaccine division of drug maker Sanofi, has completed the first study of the effects of Dengvaxia, the world's first dengue vaccine approved in Mexico, on Indian adults and is in talks to have it registered here.

The vaccine, to be injected thrice over six months, could bring relief to Indian dengue patients, whose numbers increased from 18,000 in 2011 to 74,000 in 2013, according to the Union health ministry.

"Sanofi Pasteur is in contact with the Indian authorities for registration of our vaccine," said a Sanofi Pasteur India spokesperson in reply to a question from Business Standard. CLICK HERE FOR FULL STORY

The stock opened at Rs 4,300 and touched an intraday high of Rs 4,345 on the BSE. At 10:03 am, around 2,000 shares were traded on both the stock exchanges.

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel